Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–10 of 10 results
Advanced filters: Author: Robert Landewe Clear advanced filters

  • In the second of two Perspectives articles regarding the use of MRI to detect inflammatory lesions in early preclinical axial spondyloarthritis, van der Heijde et al. defend the inclusion of MRI sacroiliitis in the 2009 ASAS classification criteria and acknowledge the importance of expert opinion in the diagnosis of this disease.

    • Désirée van der Heijde
    • Martin Rudwaleit
    • Jochen Sieper
    Reviews
    Nature Reviews Rheumatology
    Volume: 6, P: 670-672

  • Although randomized controlled trials and observational studies often reach the same conclusions, observational studies are often considered second rate. The uses, limitations, and methodological problems associated with observational studies are outlined in this article.

    • Robert Landewé
    • Désirée van der Heijde
    Reviews
    Nature Clinical Practice Rheumatology
    Volume: 3, P: 661-666

  • The ankylosing spondylitis disease activity score (ASDAS) is a measure of axial spondyloarthritis (SpA) disease activity endorsed by the Assessment of SpA International Society and Outcome Measures in Rheumatology. Accumulating evidence supports the utility of ASDAS in axial SpA. So, is it time to replace the Bath ankylosing spondylitis disease activity index (BASDAI)?

    • Pedro Machado
    • Robert Landewé
    News & Views
    Nature Reviews Rheumatology
    Volume: 9, P: 388-390

  • There is increasing evidence that treatment in the early stages of rheumatoid arthritis can significantly increase the potential for positive patient outcome and prevention of irreversible damage. This Viewpoint considers the evidence that supports aggressive treatment for early rheumatoid arthritis and investigates the available treatment options.

    • Tom WJ Huizinga
    • Robert BM Landewé
    Reviews
    Nature Clinical Practice Rheumatology
    Volume: 1, P: 2-3

  • Monitoring disease activity and physical function is a fundamental aspect of spondyloarthritis management. Advances and recommendations in the field of spondyloarthritis monitoring, both in routine care and in the presence of a specific indication, are discussed in this Review.

    • Astrid M. van Tubergen
    • Robert B. M. Landewé
    Reviews
    Nature Reviews Rheumatology
    Volume: 5, P: 608-615

  • The heterogenous nature of rheumatoid arthritis renders the prediction of responsiveness to biological treatments difficult. Here the authors analyze bulk RNA-seq data from the STRAP trial (n = 208) to build a machine-learning model for predicting responses to etanercept, tocilizumab and rituximab with AUCs around 0.75 to potentially assist in therapy planning.

    • Myles J. Lewis
    • Cankut Çubuk
    • Anne Barton
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-18